Videos

Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.

Aaron Gerds, MD, discusses the phase 3 MOMENTUM trial on momelotinib treatment for patients with myelofibrosis, including those with anemia, which served as the basis for the approval of momelotinib by the US FDA.

Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.

Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.